Drug intelligence / Profile preview

panipenem + betamipron

Development stage
Unknown
Lead developer
Daiichi Sankyo
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Panipenem + betamipron** is a fixed-dose intravenous carbapenem antibacterial combination marketed in Japan as **Carbenin**. Panipenem is a broad-spectrum beta-lactam carbapenem that bactericidally inhibits bacterial penicillin-binding proteins, disrupting peptidoglycan cross-linking and cell-wall synthesis. Betamipron is a renoprotective adjunct that reduces renal tubular uptake of panipenem, mitigating panipenem-associated nephrotoxicity. The product is approved in Japan for susceptible bacterial infections across multiple sites, including sepsis, respiratory, urinary, intra-abdominal, biliary, gynecologic, central nervous system, skin and soft-tissue, bone-and-joint, ophthalmic, otolaryngologic, and oral-maxillofacial infections. ([pmda.go.jp](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_6139503D1027_2_08))

Brand names
Carbenin
Other names
PAPM/BPpanipenem and betamipronpanipenem-betamipronpanipenem/betamipron
02

Targets

PBP (Penicillin-binding protein family)OAT (Organic anion transporter family)

Beyond the preview

Go deeper on panipenem + betamipron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on panipenem + betamipron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call